Valeant goes hostile in bid for Allergan

Valeant Pharmaceuticals makes its promised hostile play in a $53 billion attempt to take over Botox-maker Allergan. Valeant Pharmaceuticals is preparing to officially launch its long-promised hostile takeover bid for Allergan (NYSE:AGN), aiming to solicit support from Allergan shareholders to host a special meeting outside of the company's control. Pershing Capital Management, Valeant Pharmaceuticals, Allergan Inc.News Well, Cosmetic/Aesthetic, Mergers & Acquisitions, Pharmaceuticals, Wall Street Beatread more
Source: Mass Device - Category: Medical Equipment Authors: Source Type: news